Emerging Roles for AKT Isoform Preference in Cancer Progression Pathways

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• The phosphoinositol-3 kinase (PI3K)-AKT pathway is a key regulator of cell growth and survival, frequently dysregulated in human cancers.
• Mutations in PTEN, PIK3CA, and AKT1 are common drivers of PI3K-AKT pathway activation in various solid tumors.
• Current PI3K/AKT inhibitors show limited efficacy as monotherapies in solid tumors, suggesting a need for more targeted approaches.

Purpose of the Study:

• To review recent findings on the differential roles of AKT isoforms (AKT1, AKT2, AKT3) in cancer progression.
• To elucidate the complex interplay of PTEN, PI3K isoforms, and tyrosine kinases in mediating AKT isoform activation.
• To discuss the implications of isoform-specific targeting for improving PI3K/AKT inhibitor efficacy.

Main Methods:

• Literature review of recent preclinical and clinical studies.
• Analysis of signaling networks involving PTEN, PI3K, AKT isoforms, and receptor tyrosine kinases.
• Synthesis of data on the functional roles of individual AKT isoforms in oncogenesis.

Main Results:

• AKT isoforms exhibit distinct functions in promoting or suppressing specific aspects of cancer progression.
• Differential activation of AKT isoforms is orchestrated by intricate interactions between PTEN, PI3K isoforms, and upstream kinases.
• Few AKT isoform-specific substrates have been identified, highlighting a gap in understanding their unique signaling.

Conclusions:

• Targeting specific AKT isoforms, rather than the entire PI3K-AKT pathway, is crucial for developing effective cancer therapies.
• Understanding the complex regulatory mechanisms of AKT isoform activation is essential for rational drug design.
• Future PI3K/AKT inhibitor strategies should focus on isoform-selective targeting to overcome resistance and improve clinical outcomes in solid tumors.